Midweek Takeaway featuring Tim McCarthy, CEO of ImmuPharma #IMM
Season 11, Episode 20, Nov 26, 07:30 AM
Share
Subscribe
In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, CEO of ImmuPharma, for an in-depth update on the company’s P140 autoimmune platform. Tim explains why partnering discussions have attracted strong interest from multiple potential collaborators, including several top ten global pharma companies, and why the complexity and scale of that interest means a deal is now expected in 2026 rather than year-end 2025. He talks through what “finding the right partner” really looks like, how different deal structures might work (upfront payments, milestones, royalties), and why management remains very confident that a transformational licensing agreement will be secured despite the extended timeline.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.